RT Journal Article
SR Electronic
T1 Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 60S
OP 72S
DO 10.2967/jnumed.121.262977
VO 62
IS Supplement 3
A1 Pandit-Taskar, Neeta
A1 Iravani, Amir
A1 Lee, Dan
A1 Jacene, Heather
A1 Pryma, Dan
A1 Hope, Thomas
A1 Saboury, Babak
A1 Capala, Jacek
A1 Wahl, Richard L.
YR 2021
UL http://jnm.snmjournals.org/content/62/Supplement_3/60S.abstract
AB The use of radiopharmaceutical therapies (RPTs) in the treatment of cancers is growing rapidly, with more agents becoming available for clinical use in last few years and many new RPTs being in development. Dosimetry assessment is critical for personalized RPT, insofar as administered activity should be assessed and optimized in order to maximize tumor-absorbed dose while keeping normal organs within defined safe dosages. However, many current clinical RPTs do not require patient-specific dosimetry based on current Food and Drug Administration–labeled approvals, and overall, dosimetry for RPT in clinical practice and trials is highly varied and underutilized. Several factors impede rigorous use of dosimetry, as compared with the more convenient and less resource-intensive practice of empiric dosing. We review various approaches to applying dosimetry for the assessment of activity in RPT and key clinical trials, the extent of dosimetry use, the relative pros and cons of dosimetry-based versus fixed activity, and practical limiting factors pertaining to current clinical practice.